The Potency of Arterial chemo-embolization for hyper-Vascularized liver Tumors using drug eluting beads a prospective observational Investigation (PARVATI-study)

The Potency of Arterial chemo-embolization for hyper-Vascularized liver Tumors using drug eluting beads a prospective observational Investigation (PARVATI-study) - The Potency of Arterial chemo-embolization for hyper-Vascularized liver Tumors using drug eluting beads a prospective observational Investigation (PARVATI-study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020832

Enrollment

300

Registered

2016-02-01

Start date

2016-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyper-vascularized liver tumors

Interventions

DEB-TACE for hyper-vascularized liver tumors. Farmorubicin (70mg) or irinotecan (100mg) are used for eluting agents.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Hyper-vascularized liver tumors 2.Sufficient liver function 3.Informed consent from patient

Exclusion criteria

Exclusion criteria: 1.Systemic shunt in the liver 2.Not hyper-vascularized 3.bleeding tendency. Platelet counts less than 30000 or PT% less than 50% 4.Allergy for contrast medium 5.Creatinine over 1.5mg/dl 6.Other reasons which primary doctors judged not eligible for this study

Design outcomes

Primary

Measure	Time frame
Over-all survival.	—

Countries

Japan

Contacts

Public ContactTakamasa Ohki

Mitsui Memorial Hospital Gastroenterology

anb72547@nifty.com03-3862-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026